A Phase 1/2 interventional study of ZG006 in Neuroendocrine Carcinoma, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Carcinoma, Neuroendocrine with a site in China — 26 open to participants now, 27 under way, 4 of them phase 3. Carcinoma, Neuroendocrine · China.
Among the 39 studies in Carcinoma, Neuroendocrine with a site in China, this one is the 18th largest by planned enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2024, is one of 9 in phase 1/2, reaches primary completion later than 2 of the 26 other live ones, and was the 23rd registered.
172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.
Browse Carcinoma, Neuroendocrine studies →26 of the 39 studies in Carcinoma, Neuroendocrine with a site in China are open now. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–80
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Sites in China
Ages 18–70
Hansoh BioMedical R&D Company · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 47 Carcinoma, Neuroendocrine studies recruiting now, 30 (64%) set no upper age limit and 10 (21%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 24 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is above the median of 60 across 144 interventional studies indexed under Carcinoma, Neuroendocrine.
Median enrollment 80 across the 32 interventional studies, 120 across the 7 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 39 have an industry lead sponsor. The 10 most frequent:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd has 7 studies filed under Carcinoma, Neuroendocrine — fewer than ten, so there is no comparison to draw.
11 of the studies in Carcinoma, Neuroendocrine with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06070740Peking Union Medical College HospitalFirst- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma | 2026-11-30 |
| NCT07911423Peking Union Medical College HospitalImmunotherapy in Neuroendocrine Carcinoma of the Cervix | 2026-12-01 |
| NCT07879339Peking Union Medical College HospitalMulti-omics Study of Cervical Neuroendocrine Carcinoma | 2026-12-01 |
| NCT06157827Nanjing Leads Biolabs Co.,LtdA Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | 2026-12-28 |
| NCT07014540Beijing GoBroad HospitalA Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 39 studies in Carcinoma, Neuroendocrine with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label phase I/II study, divided into 2 parts:
Part 1 involves a dose-escalation study of ZG006 in which the safety and tolerability of ZG006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma are explored. Upon completion of Part 1, investigators and the sponsor will discuss and determine two recommended phase II doses (RP2D) based on safety, preliminary efficacy, and pharmacokinetic results for use in Part 2.
Part 2 is a phase II dose-expansion study of ZG006, aiming to investigate the efficacy and safety of ZG006 in patients with Neuroendocrine Carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of six dose escalations were preset: 0.1 mg, 0.3 mg, 1 mg, 3 mg.
Biological: ZG006
Participants will receive the RP2D identified in Dose Escalation Study .
Biological: ZG006
ZG006 will be administered as an intravenous (IV) infusion.
Objective response rate (ORR)
ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response(PR) based on RECIST 1.1 criteria.
Time frame: Up to approximately 2 years
Number of participants with adverse events (AEs)
The types and frequencies of adverse events (AEs) evaluated according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 5.0
Time frame: Up to approximately 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for May 2026, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alveltamig
Suzhou Zelgen Biopharmaceuticals Co.,Ltd →